the group's early november launch is planned at a time when the markets are weak
Framlington healthcare fund manager Antony Milford is to head up the group's forthcoming Biotech unit trust to be launched in early November. The group has been considering a biotech play for some time and believes now is the perfect time to bring one out as markets are weak. Milford said: 'This year biotechs have been beaten up in line with the Nasdaq Index as they have wrongly been put into the same category as technology stocks. Fundamentally there is no correlation between the two, as unlike tech, biotech companies are not affected by the economy.' In the last seven months there h...
To continue reading this article...
Join Professional Adviser for free
- Unlimited access to real-time news, industry insights and market intelligence
- Stay ahead of the curve with spotlights on emerging trends and technologies
- Receive breaking news stories straight to your inbox in the daily newsletters
- Make smart business decisions with the latest developments in regulation, investing retirement and protection
- Members-only access to the editor’s weekly Friday commentary
- Be the first to hear about our events and awards programmes